RxDoctor Payments Data

Jose Meller, MD

Cardiovascular Disease · New York, NYNPI 1629092259

Payments from drug & device makers

$208,370in general payments, 2019–2025

Across 832 payments — averaging $250.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$58K
  • Boehringer Ingelheim$53K
  • Amgen$37K
  • Esperion Therapeutics, Inc.$28K
  • Lilly USA, LLC$15K
  • Daiichi Sankyo Inc.$7K
  • plus $11K from 33 others

What the payments were for

  • Consulting fees$10,6755%
  • Speaking & faculty fees$167,21280%
  • Travel & lodging$9,3024%
  • Food & beverage$21,05810%
  • Education$1230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$208,370 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$290,437
Medicare patients
843
Services billed
3,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban564$463,398
XareltoRivaroxaban433$382,576
JardianceEmpagliflozin258$239,438
Repatha SureclickEvolocumab252$153,228
EntrestoSacubitril/Valsartan80$93,608
OzempicSemaglutide87$85,800
Praluent PenAlirocumab83$45,763
FarxigaDapagliflozin Propanediol50$35,495
MultaqDronedarone Hcl27$30,578
Ezetimibe989$26,841
LivaloPitavastatin Calcium33$15,013
RybelsusSemaglutide14$13,313
JanuviaSitagliptin Phosphate18$13,041
Nebivolol Hcl138$9,693
TenorminAtenolol12$9,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,733$463,398564 claims
Johnson & JohnsonXarelto$57,687$382,576433 claims
Boehringer IngelheimJardiance$53,471$239,438258 claims
Novo NordiskOzempic, Rybelsus$991$99,113101 claims
NovartisEntresto$936$93,60880 claims
AstraZenecaFarxiga, Crestor, Brilinta$767$50,15183 claims
Sanofi-aventis U.S. LLCMultaq$209$30,57827 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$455$24,22560 claims
MerckJanuvia$493$13,04118 claims
Arbor Pharmaceuticals, Inc.Edarbi$59$5,98516 claims
AbbVieSynthroid$157$2,81845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →